Understanding ReNU2
What families and clinicians need to know about a newly recognized cause of severe neurodevelopmental and epileptic conditions in children — including the latest research published in March 2026.
This page is for informational purposes only and does not constitute medical advice.
ReNU2 United was founded to support families affected by ReNU2—a neurodevelopmental disorder caused by variants in the gene RNU2-2. This discovery was unexpected, because RNU2-2 was long considered inactive, or a "pseudogene." We now know it plays a vital role in early brain development, and that small changes within it can have profound consequences for children.
In March 2026, three landmark studies published in Nature Genetics significantly expanded our understanding of ReNU2. These papers confirmed that the condition is far more common than previously realized, described a second inherited form of the disorder, and provided new tools for diagnosis. This page reflects those findings.
The Gene Behind ReNU2: RNU2-2
RNU2-2 encodes a molecule called U2 snRNA (small nuclear RNA), which is a working part of a large molecular machine inside every cell called the spliceosome. The spliceosome's job is to process nearly all of the body's gene transcripts — removing non-coding segments so that functional proteins can be made. Because this process affects virtually the entire genome, disruptions to spliceosome components can have wide-reaching effects on development.
Unlike most disease-causing genes, RNU2-2 does not produce a protein directly. It produces an RNA molecule that becomes part of this larger machinery. This is part of why it was overlooked for so long — it doesn't show up on standard genetic tests, and it was historically labeled a non-functional "pseudogene."
The human genome contains two closely related U2 genes: RNU2-2 and RNU2-1. In individuals without RNU2-2 variants, both genes contribute to the cell's supply of U2 RNA. When RNU2-2 variants are present and disrupt its function, RNU2-1 can partially compensate — but not fully. Research shows that in individuals with two defective copies of RNU2-2, the amount of U2-2 RNA in cells drops by more than 90%, while total U2 RNA levels remain roughly normal because RNU2-1 compensates. The ratio of U2-2 to U2-1 RNA is now recognized as a meaningful diagnostic signal.
The Two Forms of ReNU2
Research has now clearly established that RNU2-2 causes two distinct forms of disease depending on how many copies of the gene are affected. Both forms cause serious neurological conditions, but they differ in how they are inherited, how they arise, and in some of their clinical features.
Dominant (De Novo) Form 1 Copy Affected
Caused by a spontaneous new mutation that arises in the child and is not inherited from either parent. Because only one copy of the gene is affected, this is called a dominant variant.
Two specific positions in RNU2-2 — n.4G>A and n.35A>G — account for nearly all dominant cases. Because these are recurrent mutations, the variant spectrum is narrow. The dominant form is closely related to ReNU Syndrome, which is caused by variants in the related gene RNU4-2.
Typically affects only one child per family. Risk of recurrence in future pregnancies is low unless a parent carries a mosaic variant.
Recessive (Inherited) Form 2 Copies Affected
Results from inheriting one defective copy of RNU2-2 from each parent. Each parent typically carries one copy and is unaffected themselves. Because both copies must be altered, this is called biallelic or recessive inheritance.
The variants causing the recessive form occur at many different positions throughout the gene — a much wider range than the dominant form. A significant proportion of affected children carry two different variants (compound heterozygous), including de novo variants that arose spontaneously and were then inherited alongside a parental variant.
Multiple affected siblings are possible and have been documented across research cohorts. The recessive form is at least twice as frequent as the dominant form.
The Scientific Discovery
How It Was Found
The dominant form of ReNU2 was first identified through analysis of the UK's 100,000 Genomes Project — a large national program sequencing the complete genomes of patients with rare diseases and their families. When researchers analyzed children with unexplained neurodevelopmental conditions, RNU2-2 emerged as a highly significant finding alongside the closely related gene RNU4-2 (which causes ReNU Syndrome).
The initial discovery involved a small cohort of children, each carrying a spontaneous (de novo) mutation. The findings were then confirmed in separate datasets. In the years that followed, research teams across multiple countries began identifying additional affected children.
Why This Was Surprising
RNU2-2 was originally classified as a pseudogene — a genetic relic assumed to serve no function. Research showed it is in fact active and essential during development. Additionally, RNU2-2 is absent from standard exome capture panels, was historically mislabeled as a pseudogene in databases, and the related RNU2-1 gene is absent from the older GRCh37 reference genome — three compounding reasons why it was missed for so long.
When researchers examined blood from affected children, they did not find the characteristic abnormal RNA splicing patterns seen in other splicing disorders. For the recessive form, what is detectable in blood is a reduction in U2-2 RNA (the loss-of-function signal), not a splicing error in other genes. This distinction matters for how laboratory testing is designed.
The March 2026 Papers
Three studies published simultaneously in Nature Genetics in March 2026 represent the most comprehensive characterization of RNU2-2 disorders to date. Together they analyzed thousands of patients across the UK, France, Sweden, Saudi Arabia, South Korea, Australia, and other countries.
One of these papers explicitly cites this website — noting that the condition has been "recently named ReNU2 syndrome by a family foundation (renu2.org)." All three papers establish the recessive form as among the most significant genetic causes of neurodevelopmental and epileptic conditions currently known.
Greene et al. (2026); Leitão/Nava et al. (2026); Jackson/Banka et al. (2026). Nature Genetics.
How Common Is This?
One of the most striking findings from the 2026 research is just how frequently RNU2-2 variants are found when clinicians look for them with the right tools. The numbers are remarkable given that this gene was completely unknown as a disease cause just a few years ago.
In the UK 100,000 Genomes Project, the recessive form of RNU2-2 was the only recessive disorder in the top 20 most frequent diagnoses overall — sitting alongside predominantly dominant conditions. The dominant form of ReNU2 (related to ReNU Syndrome) was also among the top diagnoses, making the RNU2-2 gene family one of the most medically significant recently discovered.
A large French study (PFMG2025) analyzed more than 34,000 patients with rare disorders and found 141 individuals from 122 unrelated families with RNU2-2 variants — reinforcing that these variants are being found consistently once clinicians know to look.
Across all RNU2-2 variants combined (both forms), together with the closely related RNU4-2 gene disorders, this group of conditions — sometimes called RNU-opathies — accounts for an estimated 1.5% of previously unsolved neurodevelopmental disorders in large genome sequencing programs. That is a substantial proportion for any single gene.
Symptoms and Clinical Features
Both forms of ReNU2 cause a range of neurological and developmental challenges. There is meaningful overlap between the dominant and recessive forms, but several features are more strongly associated with one form than the other. The condition is often described as a developmental and epileptic encephalopathy (DEE).
Features common to both forms
More prominent in the recessive form
Spasticity: Increased muscle tone or stiffness, significantly more common in children with biallelic variants than in the dominant form.
Very early seizure onset: Seizures beginning in the first year of life appear more frequently in the recessive form.
Myoclonic seizures: This specific seizure type is seen in roughly three-quarters of biallelic patients, compared to under one-third in the dominant form.
Movement disorders: Problems with movement control beyond basic motor delay — such as abnormal movements or coordination difficulties — are reported in about half of recessive cases.
More prominent in the dominant form
Stereotyped hand movements: Repetitive hand movements or hand-wringing behaviors appear more frequently in children with dominant variants.
Dysmorphic facial features: Subtle facial differences — such as a broad forehead, midface differences, and down-slanting eye openings — are more consistently described in dominant cases, though they can be subtle.
Febrile seizures: Seizures triggered by fever are more associated with the common dominant variant at position n.4G>A.
ReNU2 vs. ReNU Syndrome (RNU4-2): How do they compare?
ReNU2 is closely related to ReNU Syndrome, caused by variants in RNU4-2. Both genes encode components of the same spliceosome machinery. The conditions share significant clinical overlap — seizures, intellectual disability, developmental delay — and both forms are now recognized as part of the broader family of RNU-opathies.
However, the recessive form of ReNU2 tends to involve more severe epilepsy and more prominent motor features than the dominant form or ReNU Syndrome. The dominant forms of both conditions are more similar to each other than either is to the recessive form. ReNU2 United works closely with the ReNU Syndrome community given this shared biology.
Diagnosis and Genetic Testing
Because RNU2-2 is a non-coding gene, it is invisible to many standard genetic tests. Understanding which tests can and cannot detect ReNU2 is important for families and the clinicians who care for them.
| Test Type | Detects ReNU2? | Notes |
|---|---|---|
| Whole Genome Sequencing (WGS) | ✔ Yes | Sequences all DNA, including non-coding regions. Currently the primary method for identifying RNU2-2 variants. Both dominant and recessive forms are detectable. |
| Targeted Variant Testing | ✔ Yes | Once a specific variant is identified in a family, targeted testing can confirm whether relatives carry the same change — useful for carrier testing in parents and siblings. |
| RNA Ratio Testing (U2-2:U2-1) | ✔ Yes (recessive) | In blood samples, the ratio of U2-2 to U2-1 RNA is a specific marker for biallelic (recessive) cases. Affected individuals show a significantly lower ratio than unaffected people. This is a newer tool specific to the recessive form. |
| Whole Exome Sequencing (WES) | ✘ No | Only examines protein-coding genes. RNU2-2 is non-coding and will not appear on this test. Many families with ReNU2 have had unrevealing exome results before WGS was pursued. |
| Standard Autism / ID Gene Panels | ✘ No | Typically limited to coding genes. RNU2-2 is not included on standard clinical panels at most laboratories. |
| Custom Gene Panels | ~ Sometimes | Providers can request custom panels that include RNU2-2, but only if they are specifically requested. As clinical awareness grows, more laboratories may add this gene to relevant panels. |
A note on interpreting variants in RNU2-2
RNU2-2 variants can be challenging to interpret even when detected by WGS. Because this gene is highly repetitive and was historically labeled as non-functional, variant databases may not yet contain robust information on specific changes. The 2026 research provides clearer criteria for assessing pathogenicity — particularly for the recessive form, where statistical evidence from large cohorts now strongly supports specific variants as disease-causing.
Families are encouraged to work with a genetic counselor who is familiar with RNU2-2 disorders, or to seek consultation at a center with experience in this area. Jillian O'Toole, MS, LCGC at Boston Children's Hospital is a genetic counselor with familiarity with RNU2-2.
Connect With ReNU2 United
Whether you are a family navigating a new diagnosis or a clinician seeking more information, we are here to help connect you with support and resources.
Get in TouchThis site is strictly an informational website and does not provide medical advice, diagnosis, or treatment. The content is not intended to be a substitute for professional medical advice. Always seek the advice of a physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.